Vascular Medicine
Pulmonary arterial hypertension and other pulmonary hypertension groups: risk stratification, sotatercept and vasodilator therapy.
Also called PH, PAH, pulmonary arterial hypertension
Sources: 12 new papers · 5 key papers · updated Oct 20, 2026
Unverified · drafted by AI from the sources cited below
Pulmonary hypertension is defined by increased vascular resistance in the pulmonary circulation, which is usually secondary to heart or lung diseases.1
Clinical Characteristics and Transplant-Free Survival Across the Spectrum of Pulmonary Vascular Disease
Journal of the American College of Cardiology — Hemnes A
111 citations · 2022 · among the most cited on Pulmonary hypertension
Eisenmenger Syndrome
Journal of the American College of Cardiology — Arvanitaki A
94 citations · 2022 · among the most cited on Pulmonary hypertension
Exercise Stress Echocardiography of the Right Ventricle and Pulmonary Circulation
Journal of the American College of Cardiology — Gargani L
86 citations · 2023 · among the most cited on Pulmonary hypertension
Impact of Periprocedural Pulmonary Hypertension on Outcomes After Transcatheter Aortic Valve Replacement
Journal of the American College of Cardiology — Miyamoto J
64 citations · 2022 · among the most cited on Pulmonary hypertension
Predictors of outcomes in mild pulmonary hypertension according to 2022 ESC/ERS Guidelines: the EVIDENCE-PAH UK study
European Heart Journal — Karia N
47 citations · 2023 · among the most cited on Pulmonary hypertension
A clinical question appears here only when its condition matches this topic, an outcome and a comparator were extracted from the studies, at least two studies and a patient count are on file, and the certainty is low or higher.
Supports benefit, no benefit shown, and mixed describe the direction of the measured effect. No benefit shown means the evidence does not support a benefit. It is not a finding of harm. Too little evidence means the question did not clear that bar.
Study count, RCT count, and patient count are separate. The patient total adds only studies that are linked into a study family and whose sample size is not flagged as implausible. A reversal is listed only when at least one randomized trial sits on each side of the change.
The overview is drafted from the guideline recommendations, trials, papers, and questions on this page, and every sentence has to cite one of them. It stays unverified until an NPI-verified clinician or a Synapse admin approves it. Approving records that person's name.
Most-cited researchers publishing on Pulmonary hypertension.
